ZAYNICH Drug Patent Profile

« Back to Dashboard

When do Zaynich patents expire, and what generic alternatives are available?

Zaynich is a drug marketed by Wockhardt Bio Ag and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in ZAYNICH is cefepime hydrochloride; zidebactam. One supplier is listed for this compound. Additional details are available on the cefepime hydrochloride; zidebactam profile page.

DrugPatentWatch^® Generic Entry Outlook for Zaynich

Zaynich will be eligible for patent challenges on May 29, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2036. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZAYNICH

US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZAYNICH

US Patents and Regulatory Information for ZAYNICH

ZAYNICH is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wockhardt Bio Ag	ZAYNICH	cefepime hydrochloride; zidebactam	POWDER;INTRAVENOUS	220787-001	May 29, 2026		RX	Yes	Yes
Wockhardt Bio Ag	ZAYNICH	cefepime hydrochloride; zidebactam	POWDER;INTRAVENOUS	220787-001	May 29, 2026		RX	Yes	Yes			Y	Y
Wockhardt Bio Ag	ZAYNICH	cefepime hydrochloride; zidebactam	POWDER;INTRAVENOUS	220787-001	May 29, 2026		RX	Yes	Yes				Y
Wockhardt Bio Ag	ZAYNICH	cefepime hydrochloride; zidebactam	POWDER;INTRAVENOUS	220787-001	May 29, 2026		RX	Yes	Yes
Wockhardt Bio Ag	ZAYNICH	cefepime hydrochloride; zidebactam	POWDER;INTRAVENOUS	220787-001	May 29, 2026		RX	Yes	Yes			Y

International Patents for ZAYNICH

See the table below for patents covering ZAYNICH around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2012303691	1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
Brazil	112013028813	derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
Canada	2833241	DERIVES 1,6-DIAZABICYCLO[3,2,1]OCTANE-7-ONE ET LEUR UTILISATION DANS LE TRAITEMENT D'INFECTIONS BACTERIENNES (1,6- DIAZABICYCLO [3,2,1] OCTAN-7-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS)
China	103619843	1，6‑二氮杂双环[3，2，1]辛‑7‑酮衍生物及其在治疗细菌感染中的用途 (1,6-diazabicyclo[3,2,1]octan-7-one derivatives and use thereof in treating bacterial infections)
Denmark	2748165

ZAYNICH (Zanidatamab?) Investment Scenario and Patent/Regulatory Fundamentals Analysis: Exclusivity, Orange Book Status, and Generic/Biosimilar Risk

Last updated: July 17, 2026

ZAYNICH’s investability hinges on two drivers: how long proprietary protections keep competitors off-label/on-label, and whether FDA review status supports durable U.S. market access. Patent and exclusivity facts determine settlement leverage in Paragraph IV litigation and govern generic entry timing; regulatory status and labeling determine payer adoption and contracting durability.

What is ZAYNICH, and what product fundamentals drive revenue durability?

Featured snippet answer: ZAYNICH’s revenue durability is determined by (1) FDA-approved indication and labeling scope, (2) exclusivity that delays generic entry, and (3) whether competitors can enter with a bioequivalent or protected formulation.

What active ingredient and dosage forms does ZAYNICH have?

No complete, verifiable drug-basis record (active ingredient, strength, dosage form, NDA/BLA number) is provided in the input. Without the drug’s FDA product identifier and label-level details, it is not possible to map ZAYNICH to Orange Book exclusivity, patent listings, or litigation-relevant claims.

What is the FDA pathway and approval history for ZAYNICH?

No FDA milestone data (application type, approval date, review designation, exclusivity grant type, prescribing information scope) is provided in the input. Without these, exclusivity countdown and label-specific competitive impact cannot be computed.

What commercial fundamentals matter most for investors in ZAYNICH?

For a non-generics-locked asset, the standard risk stack is:

• Patent estate breadth: composition, formulation, method-of-use, and manufacturing claims.
• Regulatory exclusivity: new chemical entity, new clinical investigations, pediatric exclusivity.
• Litigation posture: Paragraph IV timing, status, and settlement terms.
• Contracting risk: payer formularies depend on label breadth and comparability to rivals.

What patents protect ZAYNICH in the U.S., and how strong is the patent estate?

Featured snippet answer: ZAYNICH’s U.S. protection strength is measured by the number of listed Orange Book patents per NDA, claim scope (composition vs method vs formulation), and whether those patents are litigated or close to expiration.

How many Orange Book patents cover ZAYNICH, and what are their types?

No Orange Book patent listing data (patent numbers, assignees, expiration dates, “Orange Book” IDs, and listed uses) is provided in the input. Without the NDA/ANDA-facing patent table, an objective count and expiry ladder cannot be produced.

Who are the patent assignees and what is the enforcement posture?

No assignee list, enforcement history, or assignment chain is provided in the input. Without that, enforcement strength and settlement leverage cannot be grounded.

Which patent families likely drive the longest protection?

Without the specific patent numbers and family structure, any family-level hierarchy would be speculative.

When does ZAYNICH lose exclusivity, and what are the key expiration and exclusivity dates?

Featured snippet answer: ZAYNICH’s exclusivity date is the later of regulatory exclusivity and the last listed patent expiration (plus any pediatric exclusivity where applicable).

What are the regulatory exclusivity start and end dates?

No exclusivity grant type (NCE, 505(b)(2) exclusivity, pediatric) or grant dates are provided in the input.

What are the last patent expiration dates?

No Orange Book expiration dates are provided in the input.

What does the exclusivity timeline imply for generic launch scenarios?

No timeline inputs exist to compute earliest ANDA filing eligibility, Paragraph IV filing windows, 30-month stay outcomes, or launch date risk.

What generic entry risks exist for ZAYNICH, including Paragraph IV challenges?

Featured snippet answer: The generic risk profile depends on whether ANDA filers have viable paragraph IV certifications against Orange Book patents and whether courts have issued preliminary or final injunctions.

Are there any Paragraph IV filings for ZAYNICH?

No Paragraph IV filing or litigation records are provided in the input.

How do 30-month stay and court timelines affect entry timing?

No FDA notice letter dates, litigation docket dates, or stay expiration dates are provided.

What is the settlement or consent agreement risk?

No settlement or agreement terms are provided.

What is the Orange Book status of ZAYNICH (patent listings, FDA listings, and exclusivity indicators)?

Featured snippet answer: Orange Book status is determined by whether ZAYNICH’s NDA is listed with active patents and what exclusivity is coded for each active ingredient.

What NDA number and Orange Book listing identifies ZAYNICH?

No NDA number is provided in the input, so Orange Book record retrieval cannot be tied to the drug.

What patent claims are linked to each listed indication?

No listed indications, uses codes, or method-of-use linkages are provided.

Does ZAYNICH have pediatric exclusivity or other extension triggers?

No pediatric exclusivity indicator or extension facts are provided.

What formulation and method-of-use patents protect ZAYNICH?

Featured snippet answer: Formulation patents (composition, salts, polymorphs, particle engineering, release profile) and method-of-use patents (indication, patient population, dosing regimen) can prevent design-around even when composition patents are challenged.

What formulation technologies are covered (salt forms, polymorphs, release mechanisms)?

No formulation patent data is provided.

What clinical use claims are covered (indication, dosing, combinations)?

No method-of-use patent data is provided.

Which companies are challenging ZAYNICH, and what is the competitive landscape?

Featured snippet answer: Competitive intensity is highest when ANDA filers with established manufacturing and legal leverage target soon-to-expire Orange Book patents.

Who are the likely ANDA entrants or licensors?

No generic company names or biosimilar competitors are provided in the input.

How does ZAYNICH compare with branded and generic alternatives?

No comp set (same mechanism, same indication, same patient segment) is provided in the input.

What is the manufacturing and IP barrier to entry?

No manufacturing patent barriers are provided.

How does ZAYNICH compare with close competitors on patent life and regulatory risk?

Featured snippet answer: The “relative risk” view ranks assets by remaining patent term, litigation burden, and exclusivity headroom.

Side-by-side patent and exclusivity ladder

No competitor list, patent expirations, or exclusivity data is provided in the input.

Relative revenue exposure and timeline to generic erosion

No ZAYNICH revenue baseline, market penetration, or forecast is provided in the input.

What patent litigation affects ZAYNICH, and what is the case status?

Featured snippet answer: Litigation affects entry timing through injunction risk, 30-month stays, and settlement-based launch dates.

Court actions and procedural posture

No litigation history is provided.

Injunctions, damages exposure, or appeal risks

No case outcomes are provided.

How settlement terms influence generic launch dates

No settlement terms are provided.

What is the FDA regulatory status of ZAYNICH (label, indication breadth, and post-approval constraints)?

Featured snippet answer: FDA label scope and post-approval changes determine whether competitors can enter with partial carve-outs or whether the product is insulated by narrow dosing or population restrictions.

Current label and indication scope

No label details are provided.

Risk management requirements and REMS

No REMS requirement is provided.

Postmarketing commitments affecting future exclusivity value

No postmarketing data is provided.

Investment scenario: bull, base, and bear cases for ZAYNICH

Featured snippet answer: For a single-asset investment, the bull case assumes delay of generic entry via enforceable patents and favorable litigation outcomes; the bear case assumes early patent erosion and faster-than-modeled generic penetration.

Bull case

• Patent estate holds through key expirations.
• No successful early design-arounds.
• Pricing and contracting remain supported by label and outcomes.

Base case

• Limited erosion occurs after core patents expire.
• Competitive entry follows statutory timing (court outcomes and stays).
• Revenue declines gradually rather than step-change.

Bear case

• Core patents are invalidated or narrowed in a way that permits earlier generic entry.
• Settlement produces earlier launch than expected.
• Label becomes less differentiating due to competitive alternatives.

What would drive underwriting of each case?

No underwriting inputs such as remaining patent term, litigation calendar, NDA exclusivity end date, or pricing/volume metrics are provided in the input, so no model-based scenario probabilities can be stated.

Key Takeaways

• ZAYNICH’s investment fundamentals depend on patent and exclusivity mechanics that directly govern generic entry timing.
• No drug-identifying facts (active ingredient, NDA/BLA number, Orange Book listing, exclusivity dates, patent numbers, litigation status, settlement terms) are provided in the input, so a complete, data-backed exclusivity and risk assessment cannot be constructed.
• Any actionable investment decision requires a verified Orange Book and litigation timeline tied to the correct ZAYNICH FDA product record.

FAQs

1. How do investors determine whether ZAYNICH has a “blocking” formulation patent versus a “design-around” risk?
2. What indicators on the Orange Book predict whether Paragraph IV challenges will be filed early for ZAYNICH?
3. How does pediatric exclusivity change the effective generic entry date for ZAYNICH?
4. What settlement structures most commonly accelerate or delay generic launch for products like ZAYNICH?
5. How do method-of-use patents influence whether generics can launch “at-risk” for the same indication as ZAYNICH?

References

No sources were cited because no ZAYNICH-specific FDA, Orange Book, patent, or litigation data is present in the input.